Just a couple of days after filing for approval of the drug as a treatment small cell lung cancer (SCLC) with the US Food and Drug Administration, Spain’s PharmaMar (MC: PHM) has signed an important licensing deal for Zepsyre (lurbinectedin).
PharmaMar has entered into an exclusive licensing agreement with Ireland-incorporated Jazz Pharmaceuticals (Nasdaq: JAZZ) for lurbinectedin in the USA, with the news pushing the Spanish firm’s share higher on Thursday and a further 3% to 2.99 euros this morning. Jazz’s stock gained nearly 2.6% to $152,27 by close of trading on Thursday.
Under the terms of this agreement, PharmaMar will receive an upfront of $200 million with potential regulatory milestone payments of up to $250 million on the achievement of accelerated and/or full regulatory approval of lurbinectedin by FDA within certain timelines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze